Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | FADS1 | O60427 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.44 |
| ▸ | CDC7 | O00311 | 4/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.42 |
| ▸ | PAK4 | O96013 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.42 |
| ▸ | CLK2 | P49760 | 2/20 | 0.42 |
| ▸ | CDK7 | P50613 | 2/20 | 0.42 |
| ▸ | CDK9 | P50750 | 2/20 | 0.42 |
| ▸ | PRKX | P51817 | 2/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.42 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1229090 | 0.92 | JAK2 (0.49) | JAK2JAK1FADS1MAPK1MAPK3 | |
| SCHEMBL1229205 | 0.90 | MAPKAPK2 (0.54) | JAK2JAK1FADS1MAPK1MAPK3 | |
| SCHEMBL1230097 | 0.89 | FADS1 (0.47) | JAK2JAK1FADS1MAPK1MAPK3 | |
| SCHEMBL1229657 | 0.89 | MAPKAPK2 (0.51) | JAK2JAK1FADS1MAPK1MAPK3 | |
| SCHEMBL1229470 | 0.87 | JAK2 (0.47) | JAK2JAK1FADS1MAPK1MAPK3 | |
| SCHEMBL1230318 | 0.85 | MAPKAPK2 (0.43) | JAK2JAK1FADS1MAPK1MAPK3 | |
| SCHEMBL1229005 | 0.84 | MAPKAPK2 (0.52) | JAK2JAK1MAPK1MAPKAPK2CDK7 | |
| SCHEMBL1228651 | 0.83 | JAK2 (0.50) | JAK2JAK1FADS1MAPK1MAPK3 | |
| SCHEMBL1228963 | 0.81 | JAK2 (0.58) | JAK2JAK1FADS1CDC7DAPK3 | |
| SCHEMBL1229840 | 0.81 | MAPKAPK2 (0.51) | JAK2JAK1MAPKAPK2CDC7DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130017188-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-01-17 | — | — | US | claimed |
| EP-2459184-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | The Brigham and Women's Hospital, Inc. (US) | 2012-06-06 | — | — | EP | claimed |
| WO-2011014775-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-02-03 | — | — | WO | claimed |
| US-20090036449-A1 | Indazolesquaric Acid Derivatives as Chk1, Chk2 and Sgk Inhibitors | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | claimed |
| EP-1866288-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | Merck Patent GmbH (DE) | 2007-12-19 | — | — | EP | claimed |
| WO-2006105865-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | MERCK PATENT GMBH (DE) | 2006-10-12 | — | — | WO | claimed |
| US-20130017188-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| EP-2459184-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | The Brigham and Women's Hospital, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011014775-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20090036449-A1 | Indazolesquaric Acid Derivatives as Chk1, Chk2 and Sgk Inhibitors | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| EP-1866288-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | Merck Patent GmbH (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006105865-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | MERCK PATENT GMBH (DE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017188-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | SGK1, SGK3, SGK2 | JAK2 329/4885JAK1 241/4885FADS1 3557/4885 |
| US-20090036449-A1 | Indazolesquaric Acid Derivatives as Chk1, Chk2 and Sgk Inhibitors | CHEK2, CHEK1, SIK2 | JAK2 351/4885JAK1 568/4885FADS1 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.